| Post-transplant lymphoproliferative disorder. | |
| | |
MedLine Citation:
|
PMID: 20208963 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. Factors associated with increased risk of PTLD include mismatch of recipient and donor EBV serologic status (seronegative recipient with seropositive donor), and intensive drug-induced immunosuppression. METHODS AND RESULTS: We searched MEDLINE for articles published since 1970 to January 2009. Search terms included posttransplant lymphoproliferative disorder, immunosuppression, posttransplant malignancy, treatment, antiviral agents, rituximab, interferon alpha, chemotherapy, radiation, surgery. Studies in English of adult and pediatric populations after solid organ transplantation were selected and analyzed. CONCLUSION: Screening of patients at risk and balancing the intensity of immunosuppression against the risk of allograft rejection could reduce the risk of developing PTLD. In patients who develop PTLD, the severity and extent of disease should be examined and an individualized treatment plan including immunosuppression reduction and other agents should accordingly be chosen. |
| | |
Authors:
|
Lucie Kalinova; Jarmila Indrakova; Petr Bachleda |
Related Documents
:
|
19918163 - Aggressive posttransplant lymphoproliferative disease in a renal transplant patient tre... 11866993 - Post-transplantation lymphoproliferative disease. 12037753 - Portal venous velocity in the follow-up of patients with biliary atresia after kasai po... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Biomedical papers of the Medical Faculty of the University Palack?, Olomouc, Czechoslovakia Volume: 153 ISSN: 1213-8118 ISO Abbreviation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2010-03-08 Completed Date: 2010-05-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101140142 Medline TA: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Country: Czech Republic |
Other Details:
|
Languages: eng Pagination: 251-7 Citation Subset: IM |
Affiliation:
|
Department of Surgery II, University Hospital, I. P. Pavlova 6, Olomouc, Czech Republic. lucie.kalinova@email.cz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Epstein-Barr Virus Infections
/
complications Humans Immunosuppressive Agents / adverse effects, therapeutic use Lymphoproliferative Disorders / diagnosis, etiology*, prevention & control, therapy Transplantation / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Magnetic drug delivery and targeting: principles and applications.
Next Document: Reactivation potency of the acetylcholinesterase reactivator obidoxime is limited.